The discovery of anti-cancer drugs based on the post traductional modification of Ras protein has been thoroughly studied in the last years. The aim of the present study is to optimize the solid phase synthesis of quinazolinediones, compounds that present an inhibitory activity of the S-farnesyltransferaze (FTase). Two strategies for obtaining a new FTase inhibitor, S35028, are presented.
